Article and Video CATEGORIES
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Jonathan Riess and Suki Padda.
Jonathan W. Riess, MD MS is Associate Professor of Medicine in the Division of Hematology/Oncology at UC Davis Comprehensive Cancer Center. Sukhmani Padda MD is Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center.
The doctors discuss a series of cases related to a diagnosis of ALK Positive NSCLC. In this video, the discussion is regarding a patient with ALK positive and high PDL-1. What is the first line treatment for potentially competing targets?
For a full listing of these case based discussions, please visit https://cancergrace.org/sponsor/case-based-panel-discussions-2019-lung-cancer.
To join the conversation, visit https://cancergrace.org/forum
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…
That's beautiful Linda. Thank you,